Efficacy of acetyl-cholinesterase-inhibitor (ACHEI) treatment in Alzheimer's disease: A 21-month follow-up "real world" study

Archives of Gerontology and Geriatrics

Volumn 49, Issue 1, 2009, Pages

  Calabria, Marco ^a   Geroldi, Cristina ^a   Lussignoli, Giulia ^a   Sabbatini, Federica ^a   Zanetti, Orazio ^a  

^a IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

Author keywords

Acetyl cholinesterase inhibitor (ACHEI); Alzheimer disease (AD); Efficacy of ACHEI treatment; Observational study

Indexed keywords

DONEPEZIL; RIVASTIGMINE;

AGED; ALZHEIMER DISEASE; ARTICLE; DAILY LIFE ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 67349178199     PISSN: 01674943     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.archger.2008.07.006     Document Type: Article

References (41)

1. Adler G., Brassen S., Chwalek K., Dieter B., and Teufel M. Prediction of treatment response to rivastigmine in Alzheimer's dementia. J. Neurol. Neurosurg. Psychiatry 75 (2004) 292-294
2. Bellelli G., Lucchi E., Minicuci N., Rozzini L., Bianchetti A., Padovani A., and Trabucchi M. Results of a multi-level therapeutic approach for Alzheimer's disease subjects in the "real world" (CRONOS project): a 36-week follow-up study. Aging Clin. Exp. Res. 17 (2005) 54-61
3. Benjamin B., and Burns A. Donepezil for Alzheimer's disease. Expert Rev. Neurother. 7 (2007) 1243-1249
4. Birks, J., Harvey, R.J., 2006. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst. Rev. CD001190.
5. Birks, J., Grimley Evans, J., Iakovidou, V., Tsolaki, M., 2000. Rivastigmine for Alzheimer's disease. Cochrane Database Syst. Rev. CD001191.
6. Burns A., Rossor M., Hecker J., Gauthier S., Petit H., Moller H.J., Rogers S.L., and Friedhoff L.T. The effects of donepezil in Alzheimer's disease-results from a multinational trial. Dement. Geriatr. Cogn. Disord. 10 (1999) 237-244
7. Caffarra P., Vezzadini G., Copelli S., Dieci F., Messa G., Nonis E., and Venneri A. Comparing treatment effects in a clinical sample of patients with probable Alzheimer's disease treated with two different cholinesterase inhibitors. Acta Biomed. 78 (2007) 16-21
8. Csernansky J.G., Wang L., Miller J.P., Galvin J.E., and Morris J.C. Neuroanatomical predictors of response to donepezil therapy in patients with dementia. Arch. Neurol. 62 (2005) 1718-1722
9. Cummings J.L. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am. J. Geriatr. Psychiatry 11 (2003) 131-145
10. Di Lazzaro V., Oliviero A., Pilato F., Saturno E., Dileone M., Marra C., Ghirlanda S., Ranieri F., Gainotti G., and Tonali P. Neurophysiological predictors of long term response to AChE inhibitors in AD patients. J. Neurol. Neurosurg. Psychiatry 76 (2005) 1064-1069
11. Emre M., Cummings J.L., and Lane R.M. Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences. J. Alzheimer's Dis. 11 (2007) 509-519
12. Farlow, M.R., Lilly, M.L., ENA713 B352 Study Group, 2005. Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years. BMC Geriatr. 5, 3.
13. Folstein M.F., Folstein S.E., and McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12 (1975) 189-198
14. Geldmacher D.S. Donepezil (Aricept) for treatment of Alzheimer's disease and other dementing conditions. Expert Rev. Neurother. 4 (2004) 5-16
15. Han L., Cole M., Bellavance F., McCusker J., and Primeau F. Tracking cognitive decline in Alzheimer's disease using the mini-mental state examination: a meta-analysis. Int. Psychogeriatr. 12 (2000) 231-247
16. Hogan D., and Patterson C. Progress in clinical neurosciences: treatment of Alzheimer's disease and other dementias-review and comparison of the cholinesterase inhibitors. Can. J. Neurol. Sci. 29 (2002) 306-314
17. Hogan D., Bailey P., Carswell A., Clarke B., Cohen C., Forbes D., Man-Son-Hing M., Lactot K., Morgan D., and Thorpe L. Management of mild to moderate Alzheimer's disease and dementia. Alzheimers Dement. 3 (2007) 355-384
18. Huynh H., and Feldt L. Estimation of the Box correction for degrees of freedom from sample data in the randomized block and split-plot designs. J. Educat. Stat. 1 (1976) 69-82
19. Kaduszkiewicz H., Zimmermann T., Beck-Bornholdt H.P., and Van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. Br. Med. J. 331 (2005) 321-327
20. Lanctot K.L., Herrmann N., and LouLou M.M. Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease. J. Psychiatry Neurosci. 28 (2003) 13-26
21. Lanctot K.L., Herrmann N., Yau K.K., Khan L.R., Liu B.A., LouLou M.M., and Einarson T.R. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. Can. Med. Assoc. J. 169 (2003) 557-564
22. Lemstra A.W., Richard E., and Van Gool W.A. Cholinesterase inhibitors in dementia: yes, no, or maybe?. Age Ageing 36 (2007) 625-627
23. Loy, C., Schneider, L., 2004. Galantamine for Alzheimer's disease. Cochrane Database Syst. Rev. CD001747.
24. Mauchly J. Significance test for sphericity of a normal n-variate distribution. Ann. Math. Stat. 11 (1940) 204-209
25. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984) 939-944
26. Mohs R.C., Doody R.S., Morris J.C., Ieni J.R., Rogers S.L., Perdomo C.A., and Pratt R.D. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 57 (2001) 481-488
27. Onor M.L., Trevisiol M., and Aguglia E. Rivastigmine in the treatment of Alzheimer's disease: an update. Clin. Interv. Aging 2 (2007) 17-32
28. Poirier J., Delisle M.C., Quirion R., Aubert I., Farlow M., Lahiri D., Hui S., Bert-rand P., Nalbantoglu J., Gilfix B.M., and Gauthier S. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 12260-12264
29. Raschetti R., Maggini M., Sorrentino G.C., Martini N., Caffari B., and Vanacore N. A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease. Eur. J. Clin. Pharmacol. 61 (2005) 361-368
30. Rosen W.G., Mohs R.C., and Davis K.L. A new rating scale for Alzheimer's disease. Am. J. Psychiatry 141 (1984) 1356-1364
31. Saumier D., Murtha S., Bergman H., Phillips N., Whitehead V., and Chertkow H. Cognitive predictors of donepezil therapy response in Alzheimer disease. Dement. Geriatr. Cogn. Disord. 24 (2007) 28-35
32. Shankar, G.M., Li, S., Mehta, T.H., Garcia-Munoz, A., Shepardson, N.E., Smith, I., Brett, F.M., Farrell, M.A., Rowan, M.J., Lemere, C.A., Regan, C.M., Walsh, D.M., Sabatini, B.L., Selkoe, D.J., 2008. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med., doi:10.1038/nm1782.
33. Sinforiani E., Banchieri L.M., Zucchella C., Bernasconi L., and Nappi G. Cholinesterase inhibitors in Alzheimer's disease: efficacy in a non-selected population. Funct. Neurol. 18 (2003) 233-237
34. Sobow T., Flirski M., Liberski P., and Kloszewska I. Plasma Abeta levels as predictors of response to rivastigmine treatment in Alzheimer's disease. Acta Neurobiol. Exp. (Wars.) 67 (2007) 131-139
35. Tinklenberg J.R., Kraemer H.C., Yaffe K., Ross L., Sheikh J., Ashford J.W., Yesavage J.A., and Taylor J.L. Donepezil treatment and Alzheimer disease: can the results of randomized clinical trials be applied to Alzheimer disease patients in clinical practice?. Am. J. Geriatr. Psychiatry 15 (2007) 953-960
36. Villarroya M., Garcia A.G., Marco-Contelles J., and Lopez M.G. An update on the pharmacology of galantamine. Expert Opin. Invest. Drugs 16 (2007) 1987-1998
37. Waldemar G., Dubois B., Emre M., Georges J., McKeith I.G., Rossor M., Scheltens P., Tariska P., and Winblad B. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur. J. Neurol. 14 (2007) e1-e26
38. Wallin A.K., Andreasen N., Eriksson S., Batsman S., Nasman B., Ekdahl A., Kilander L., Grut M., Ryden M., Wallin A., Jonsson M., Olofsson H., Londos E., Wattmo C., Eriksdotter Jonhagen M., and Minthon L. Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting. Dement. Geriatr. Cogn. Disord. 23 (2007) 150-160
39. Winblad B., Engedal K., Soininen H., Verhey F., Waldemar G., Wimo A., Wetterholm A.L., Zhang R., Haglund A., and Subbiah P. A 1-year, rando-mized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 57 (2001) 489-495
40. Winblad B., Wimo A., Engedal K., Soininen H., Verhey F., Waldemar G., Wetter-holm A.L., Haglund A., Zhang R., and Schindler R. 3-Year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dement. Geriatr. Cogn. Disord. 21 (2006) 353-363
41. Wynn Z.J., and Cummings J.L. Cholinesterase inhibitor therapies and neuro-psychiatric manifestations of Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 17 (2004) 100-108